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Abstract
Universal health coverage (UHC) aims to ensure that all people have access to health services includ-
ing essential medicines without risking financial hardship. Yet, in many low- and middle-income
countries (LMICs) inadequate UHC fails to ensure universal access to medicines and protect the poor
and vulnerable against catastrophic spending in the event of illness. A human rights approach to es-
sential medicines in national UHC legislation could remedy these inequities. This study identifies and
compares legal texts from national UHC legislation that promote universal access to medicines in the
legislation of 16 mostly LMICs: Algeria, Chile, Colombia, Ghana, Indonesia, Jordan, Mexico,
Morocco, Nigeria, Philippines, Rwanda, South Africa, Tanzania, Turkey, Tunisia and Uruguay. The as-
sessment tool was developed based on WHO’s policy guidelines for essential medicines and inter-
national human rights law; it consists of 12 principles in three domains: legal rights and obligations,
good governance, and technical implementation. Relevant legislation was identified, mapped, col-
lected and independently assessed by multi-disciplinary, multi-lingual teams. Legal rights and State
obligations toward medicines are frequently codified in UHC law, while most good governance prin-
ciples are less common. Some technical implementation principles are frequently embedded in na-
tional UHC law (i.e. pooled user contributions and financial coverage for the vulnerable), while others
are infrequent (i.e. sufficient government financing) to almost absent (i.e. seeking international assist-
ance and cooperation). Generally, upper-middle and high-income countries tended to embed explicit
rights and obligations with clear boundaries, and universal mechanisms for accountability and re-
dress in domestic law while less affluent countries took different approaches. This research presents
national law makers with both a checklist and a wish list for legal reform for access to medicines, as
well as examples of legal texts. It may support goal 7 of the WHO Medicines & Health Products
Strategic Programme 2016–30 to develop model legislation for medicines reimbursement.
Keywords: Access, health insurance, legislation, human rights, essential drugs, government, accountability, health financing,
user fees, vulnerable populations, equity
Introduction
Two billion people lack access to the medicines they need (Access to
Medicines Foundation, 2015). Frequent public sector stock-outs, high
medicines prices (especially in the private sector) and inadequate basic
health insurance are major access barriers in low- and middle-income
countries (LMICs) (Wirtz et al., 2016). Faced with illness, households
may incur catastrophic spending on medicines and endure the impover-
ishing consequences (Wirtz et al., 2016). Universal access to essential
medicines is therefore an important aspect of global development and
a crucial component of universal health coverage (UHC), affirmed in
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the Sustainable Development Goal (SDG) 3 for Health. SDG Target
3.8 on UHC aims to ensure that all have access to health services
including essential medicines without risking financial hardship (UN
General Assembly, 2015). This target encompasses some aspects of the
right to health, which offers a set of standards and principles for equit-
able and inclusive access to healthcare (Ooms et al., 2014; Chapman,
2016a). Under international human rights law, governments have the
‘core obligation’ to provide essential medicines on a non-
discriminatory basis and with attention for vulnerable groups (UN
General Assembly, 1966b; UN CESCR 2000; Hogerzeil, 2006). Yet,
SDG Target 3.8 neglects important aspects of a right to health ap-
proach, such as prioritized care and financial protection for the disad-
vantaged, and international cooperation and assistance for cost sharing
with low-income countries (Ooms et al., 2014; Chapman, 2016a).
According to WHO ‘[l]aw is a powerful tool for ensuring that
the poor and vulnerable are not deprived of access to health care
services and other resources for leading a healthy life.’ (Magnusson,
2017) A total of 165 States have ratified the International Covenant
on Economic, Social and Cultural Rights (ICESCR), and therefore
they bear the irrevocable duty to ensure their domestic law, policy,
and practice protects and promotes these rights. On the path toward
UHC over 70 countries have sought guidance from WHO concern-
ing their domestic health reforms (WHO Consultative Group on
Equity and Universal Health Coverage, 2014). WHO’s Medicines &
Health Products Strategic Programme 2016–30 goal no. 7 is to de-
velop model legislation for medicines reimbursement (WHO, 2017).
Indeed, some reforms have been associated with increases in proxy
indicators of medicines access such as their sale and use (Garabedian
et al., 2012; Nazzal et al., 2016). However, UHC financing and ac-
cess in other LMICs disproportionately benefits the rich compared
with the poor (Asante et al., 2016; Alshamsan et al., 2017).
Human rights are increasingly acknowledged to help close the
equity gap in UHC (Office of the United Nations High Commissioner
for Human Rights and WHO, 2012; WHO Consultative Group on
Equity and Universal Health Coverage, 2014). They can also guide an
inclusive and accountable formulation of universal access to essential
medicines in national law and policy (Hogerzeil, 2006; Ooms et al.,
2014; Sridhar et al., 2015). In 2010, legal scholars in collaboration with
WHO produced a pilot study of national legislation for access to medi-
cines in four countries. Although this study was an important first step
to collect and compare these national laws, it did not address UHC,
likely reflecting the limited development of the concept at the time
(Forzley et al., 2010). In 2017 WHO published guidance to advise
Member States on including the right to health in domestic law, includ-
ing for UHC (Magnusson et al., 2017). However, this guidance lacks a
comprehensive approach to essential medicines as a health systems com-
modity and a component of UHC. Moreover, no practical assessment
tool is available to aid lawmakers in analysing the strengths and weak-
nesses in national law for access to medicines.
Human rights principles in national legislation are an under-
explored tool to enhance equitable medicines access through UHC
in the existing literature. In existing scholarship, multiple, in-depth
analyses of a single or small selection of countries study the evolu-
tion and impact of UHC reform on medicines and other health
services (Carapinha et al., 2011; Lagomarsino et al., 2012; Atun
et al., 2013, 2015; Balabanova et al., 2013). These studies focus
on measures of health system function (i.e. pre-payment, pooling
risk and purchasing) and of universal access (i.e. population cover-
age, services and direct costs to patients) (Hamilton et al., 2016).
However, these investigations neither use human rights law as the
frame of reference, nor do they examine the content of national
health legislation. Human rights principles (i.e. entitlements, State
obligations, participation and accountability) create an enabling
environment for patients to claim their rights and hold their gov-
ernments accountable; therefore, these principles are also import-
ant aspects of legislation (Motta Ferraz, 2011; Chapman, Forman
and Lamprea, 2017; Yamin and Maleche, 2017). Yet, previous
studies of legal or policy interventions for medicines often source
data from systematic literature reviews, websites of international
organizations and/or key informants, rather than the laws or poli-
cies themselves (Vialle-Valentin et al., 2008; Carapinha et al.,
2011; Gammie et al., 2015; Hamilton et al., 2016). This is a prag-
matic albeit weak approach considering that no global repository
of domestic health law exists and most health legislation is only
available in the official national language(s) (Attaran et al., 2012;
Levels, Sluiter and Need, 2014).
To address these shortcomings, we develop and apply an assess-
ment tool to UHC legislation in 16 mostly LMICs in order to iden-
tify legal texts that promote universal access to medicines. Our
research presents examples of legal texts for domestic lawmakers
and establishes a baseline of legal commitments to essential medi-
cines in national law; it may support the WHO Medicines & Health
Products Strategic Programme 2016–30 to develop model legislation
for medicines reimbursement (WHO, 2017).
Materials and methods
This is a cross-national study of UHC legislation for access to medi-
cines from 16 mostly LMICs. It collects, describes and compares
legal texts against an assessment tool with 12 principles for essential
medicines and human rights. A detailed description of the method-
ology is in the Supplementary Appendix (https://dx.doi.org/10.
6084/m9.figshare.6535106).
Assessment tool
To analyse the content of UHC laws, we developed an assessment
tool to identify 12 principles that are important from the perspective
of WHO’s essential medicines policies (Hodgkin et al., 2001; WHO,
Key Messages
• Health law makers in low- and middle-income countries (LMICs) lack the guidance and tools to write national legislation
that promotes universal access to essential medicines through universal health coverage (UHC).
• This is the first study to assess the text of UHC laws for principles of access to medicines, based on WHO’s policies on
essential medicines and international human rights law.
• Evidence from 16 mostly LMICs indicates that national laws often embed individual rights, government obligations,
accountability and some technical principles (i.e. coverage for vulnerable groups), while other good governance and
technical principles are infrequent.
• This article produces examples of legal text and an assessment tool, which is both a checklist for evaluating national
law and policy, and a ‘wish list’ to guide legal reform.
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2004, 2007, 2014; Bigdeli et al., 2013) and international human
rights law ( UN General Assembly, 1966a,b 2008, UN CESCR,
1991, 2000, 2006, 2007, 2016 ). (Selected international human
rights law concerned States’ obligations toward social or health
rights, the core obligation to provide essential medicines and/or
rights related to good governance.) The principles are based on over-
lapping concepts related to access to medicines for vulnerable
groups in the reference documents. The assessment tool was devel-
oped by two authors who shortlisted the relevant principles from
source documents, independently piloted the short list on UHC laws
to determine their applicability and adequacy, and revised the short
list. Three rights to health and pharmaceutical policy experts (one
author and two external reviewers) reviewed the short list to ensure
the principles were sufficient and correctly defined.
We categorized the 12 principles in three domains (Table 1):
legal rights and obligations (i.e. government’s commitments and
duties), good governance (i.e. governance principles and processes)
and technical implementation (i.e. policy measures to achieve gov-
ernment objectives). The domains correspond to the structure-
process-outcome framework for monitoring and evaluating the real-
ization of human rights (Office of the High Commissioner for
Human Rights, 2012). We describe the principles and domains in
our detailed methodology in the Supplementary Appendix
(Perehudoff et al., 2018). We hypothesize that recognizing all three
Table 1. Assessment tool for access to essential medicines in national law and policy
Principles Human rights principle WHO essential medicines policy
Legal rights and obligations
1. Right to health Right to the highest attainable standard of health
(UN General Assembly, 1966b; UN CESCR,
2000)
Human rights are a ‘value’ (Bigdeli et al., 2013)
2. State obligation to pro-
vide essential
medicines
Core obligation to provide essential medicines
defined by WHO (UN General Assembly,
1966b; UN CESCR, 1991, 2000, 2008, 2016)
Good governance
3. Transparency Transparency (UN General Assembly, 1966a,b;
UN CESCR, 2000)
Includes information to assess service access and coverage, and
publicly available price information for medicines. A component
of good governance for medicines (Hodgkin et al., 2001;
WHO, 2007, 2014)
4. Participation and
consultation
Participation (UN General Assembly, 1966a,b;
UN CESCR, 2000)
Collaboration and accountability of all health systems actors, and
stakeholder consultation is required. Referenced in good govern-
ance for medicines (Hodgkin et al., 2001; WHO, 2007, 2014)
5. Monitoring and
evaluation
Monitoring (UN General Assembly, 1966b; UN
CESCR, 2000)
Achieved through explicit government commitment, indicator-
based surveys and independent impact evaluation. A component
of good governance for medicines (Hodgkin et al., 2001;
WHO, 2007, 2014)
6. Accountability and
redress
Accountability (UN General Assembly, 1966a,b;
UN CESCR, 2000)
Accountability of all health systems actors (WHO, 2007)
Technical implementation
7. Selection of essential
medicines
(Assured) quality of health services (of the
AAAQ) (UN General Assembly, 1966b; UN
CESCR, 2000)
Includes the essential drugs concept, procedures to define and up-
date the national list(s) of essential drugs, explicit, evidence-
based criteria that includes cost effectiveness and selection mech-
anisms (Hodgkin et al., 2001; WHO, 2004)Duty to adopt appropriate legislative, administra-
tive, budgetary and other measures to a max-
imum of its available resources Core obligation
to provide essential medicines as defined by
WHO (UN General Assembly, 1966b; UN
CESCR, 1991, 2000, 2008, 2016)
8. Government financing Requires adequate funding and mobilizing all available public
resources and increase funding for priority diseases, and the vul-
nerable (Hodgkin et al., 2001; WHO, 2004, 2007)
9. Pool user contributions Medicines reimbursement with user charges is a (temporary)
financing option (WHO, 2004, 2007)
10. International assist-
ance and technical
cooperation
Duty to seek international assistance and technical
cooperation (UN General Assembly, 1966b,
2008; UN CESCR, 2000, 2007)
Includes the possibility of using development loans for medicines
financing (World Health Organization, 2004)
11. Efficient and cost-ef-
fective spending
Duty for the efficient use of available resources
Duty to take appropriate steps to ensure that the
private business sector is aware of, and consider
the importance of, the right to health in pursuing
their activities Duty to prevent unreasonably
high costs for access to essential medicines from
undermining the rights of large segments of the
population to health Duty to seek low-cost pol-
icy options (UN General Assembly, 1966b,
2008; UN CESCR, 1991, 2000, 2008)
Includes the efficient use of resources and affordable pricing
through: price control; a pricing policy for all medicines; compe-
tition through generic policies and substitution; good procure-
ment practices; price negotiation and information; and TRIPS-
compliant measures such as compulsory licensing and parallel
imports (Hodgkin et al., 2001; World Health Organization,
2004, 2007)
12. Financial protection
of vulnerable groups
Duty toward non-discrimination and attention to
the vulnerable (UN General Assembly, 1966b;
UN CESCR, 2000, 2008)
Increase government funding for poor and vulnerable groups and
reduce the risk of catastrophic health spending (World Health
Organization, 2004, 2007)
Abbreviations: WHO, World Health Organization; AAAQ, availability, accessibility, acceptability and quality.
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domains in UHC legislation will generate more predictable, trans-
parent and accountable rights and obligations, leading to greater re-
sponsiveness to the poor and vulnerable, equity, and sustainability.
Country selection
We selected 16 countries that have ratified the ICESCR, have a na-
tional health insurance system and had a low- or middle-income
economy in 2015, with the exception of Chile and Uruguay (became
high -income countries in 2012 (World Bank, n.d.). Our sample
achieves maximum variation of WHO regions, legal families (WHO
classification) and income economies (World Bank 2015 classifica-
tion) (Table 2) (World Bank, n.d.; WHO, 2016).
Collection of legislation
We convened multi-disciplinary country research teams (with law/
medicine backgrounds) fluent in the official national language and
English. Teams compiled 16 country profiles to describe the national
health and legal context of access to medicines, and the relevant na-
tional laws (objectives, interrelationships with other legal instru-
ments and text related to medicines). (The profiles are accessible
here: https://figshare.com/projects/Legislating_for_universal_access_
to_medicines_A_rights-based_cross-national_comparison_of_UHC_
laws_in_16_countries/35054.)
First, teams identified relevant national laws by searching national
government websites, online databases of national law and policy, ref-
erence lists in related academic and policy publications and cross-
references in national legislation to other relevant laws. Second, teams
mapped the relationship between laws, and cross-referenced our list
with academic publications and governmental or other reports to verify
that our collection was complete and current. Third, laws were selected
for analysis if they were relevant for access to medicines for vulnerable
groups and if they addressed at least one principle in the assessment
tool. Laws governing the regulation, control and marketing of pharma-
ceuticals, or private health insurance were excluded. Fourth, at least
one pharmaceutical policy expert from each country except Nigeria
and Algeria reviewed our list of legislation for relevance and currency.
Most legal texts were extracted from the legislation first by one re-
search team member, followed by one author who verified and supple-
mented the initial text selection. Selected texts were translated to
English and, where possible, peer-reviewed by a second team member.
Data analysis
Two authors each independently coded the strength of each prin-
ciple in the legal texts on a three-point coding matrix (i.e. strong,
weak or absent text) defined in the detailed methodology (see
Supplementary Appendix). Generally, strong text includes a clear
State commitment to a principle and an action (i.e. to adhere to the
concept of essential medicines and introduce a national selection
committee) and where possible related to medicines affordability
and financing. Weak text includes vague commitments. Coders dis-
cussed disagreements until consensus was reached. Pharmaceutical
policy experts (explained above) were invited to provide written
comments on our preliminary results; minor changes were made to
some codes due to more recent laws or differences of interpretation.
We reported the most and least frequent principles in national
UHC law. For each principle we described the different approaches
in different countries.
We also examined a relationship between the principles and national
level of economic development by converting the legal recognition of
each principle to a binary score: strong text or weak/absent text and
compared with national economic development using the Fischer’s Exact
Test (performed with SPSS version 25 with significance set at P¼0.05).
Results
We included 86 domestic laws from 16 countries, ranging from two
laws per country (Nigeria and Ghana) to 10 laws per country
(Colombia) (see list in the Supplementary Appendix: https://dx.doi.
org/10.6084/m9.figshare.6537452).
The strength of the 12 principles in UHC legislation is shown by
country in Table 2. Legislation with innovative ideas is listed for each of
the 12 principles in Table 3 (see full text examples in the Supplementary
Appendix: https://dx.doi.org/10.6084/m9.figshare.6538403).
The most common principles are pooling user contributions (n¼10
countries), rights (n¼9), accountability (n¼9), obligations (n¼8) and
financial coverage for the vulnerable (n¼8). The least common princi-
ples are from the governance domain (monitoring, transparency, partici-
pation, n¼2–3) and the technical domain (international cooperation
n¼1). Overall, UHC legislation from Colombia, Chile, Mexico and the
Philippines codifies a high number of principles.
12 principles for access to medicines in national law
Right to health
Medicines are an explicit entitlement in Colombia, Mexico and
Uruguay. A less specific universal right to health or services is found
in Ghana, Tunisia, Chile, Indonesia and Turkey. Other national le-
gislation did not address the right to access healthcare nor medi-
cines, except the Philippines (right is conditional on financial
contribution) and Nigeria (all are entitled to a basic minimum pack-
age of health services).
State obligation
Chile, Colombia, Indonesia, Mexico, the Philippines and Uruguay
specify strong State obligations to pharmaceutical care. Uruguay
and Chile require the State to guarantee access or ensure the avail-
ability of medicines in the national formulary for all people. The
State is explicitly required to ensure access to pharmaceuticals with-
out payment at the point of service and without discrimination
(Mexico), to make essential goods affordable to all (Philippines), or
to guarantee the essential medicines are equally available and afford-
able to the public (Indonesia). The Colombian government is re-
sponsible for respecting, protecting and ensuring the enjoyment of
the fundamental right to health (including the provision of medi-
cines) in line with the terms in General Comment No. 14.
State responsibilities are somewhat weak in Algeria, Jordan,
Morocco and Tunisia. In Algeria, medicines prescribed in public
health facilities are provided free-of-charge for in- and out-patients.
African countries did not codify any State obligations toward health,
with the notable exception of Ghana (to attain UHC) and South
Africa (to provide healthcare to those without other forms of insur-
ance, and some women and children).
Transparency
Transparency in pharmaceutical policy is observed in South Africa
(price transparency), the Philippines (price ceilings and public dis-
seminating of that information) and Chile (database of drug prices
and medicines evaluation reports). The Philippines law has a com-
prehensive dissemination strategy targeting newspapers, television
and posters in public markets, supermarkets and other public places.
Domestic health law most often framed transparency as informa-
tion about the benefits package and procedure for accessing it
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(South Africa, Ghana, Philippines, Mexico, Uruguay, Colombia),
the rights of patients (South Africa, Nigeria, Rwanda, Ghana,
Turkey, Chile) and the complaints procedure (South Africa, Nigeria,
Ghana, Colombia, Chile).
Participation and consultation
Patient/consumer participation in domestic pharmaceutical policy is
permitted by law in Colombia (users who are trained physicians can
join the Pharmacy Commission), Chile (patients may participate in
the technical advisory commission recommending priority for high
cost medicines) and Mexico (community participation, including to
inform the authorities about medicines-related side effects and ad-
verse reactions).
General community participation or empowerment in relation to
health involve users in national consultation forums, decision-
making bodies, National Health Council or Patient Rights Boards
(Colombia, Mexico, Philippines, Rwanda, South Africa, Tanzania,
Turkey and Uruguay). Laws require health authorities and govern-
ing boards to include geographic representatives and women
(Nigeria, Ghana), workers (Algeria) or a representative of the
national league for the defence of human rights (Tunisia). Jordan
and Indonesia do not address the concept of participation.
Monitoring and evaluation
The Philippines’ Act on Universal Access and Quality Medicines is
the only law in our sample to adopt a patient-centred approach to
monitoring medicines prices and affordability. It requires regular
surveys of sales prices of medicines and their effect on the household
income of different economic groups. Other medicines-specific mon-
itoring is mentioned in laws from Nigeria (‘good drug use’), Algeria
(‘the market situation’ of medicines). Mexican legislation requires a
periodic evaluation of the healthcare system related to eliminating
financial and organisational barriers to accessing services and the ac-
cess and supply of medicines. All countries except Turkey prescribe
general monitoring of the health insurance or system.
Accountability and redress
The right to complain is codified in the domestic health legislation
of Colombia, Chile, South Africa and Nigeria (about the manner of
treatment), Turkey (in the event of infringement of patient rights),
Table 3. Innovative ideas for medicines affordability and financing in national UHC legislation
1. Right to health including essential medicines
Indonesia: Law No. 36/2009 (2009)
Mexico: General Health Law (2017)
2. State duty to provide pharmaceuticals
Philippines: National Health Insurance Act (2013)
Mexico: General Health Law (2017)
3. Transparency of governments’ action and outcomes for medicines affordability
Philippines: Republic Act No. 7581 (1992), Republic Act No. 9502 (2008)
Chile: Law No. 20584 (2012)
4. Participation and consultation for medicines affordability
Colombia: Law No. 100 (1993)
Chile: Law No. 20850 (2015)
5. Monitoring and evaluation for medicines affordability
Philippines: Republic Act No. 9502 (2008)
Mexico: Regulations of the General Health Law in the matter of social protection in health (2014)
6. Accountability and redress for medicines affordability
Turkey: Patient Rights Regulation (2016)
South Africa: National Health Amendment Act No. 12 (2013)
7. Selection of essential medicines
Ghana: National Health Insurance Act No. 852 (2012)
Indonesia: Law No. 40/2004 (2004), Law No. 36/2009 (2009)
Uruguay: Law No. 18.211 (2007), Decree No. 265/006 (2006)
8. Sufficient government financing for essential medicines
Rwanda: Law No. 03/2015 (2015)
Philippines: National Health Insurance Act (2013)
Nigeria: National Health Act No. 8 (2004)
9. Pooling user contributions for essential medicines
Ghana: National Health Insurance Act No. 852 (2012)
Morocco: Law 65-00 (2002), Decree No. 2-08-177 (2008)
Philippines: National Health Insurance Act (2013)
Turkey: Law No. 5510 (2006)
10. International assistance and technical cooperations for medicines affordability
Nigeria: National Health Act No. 8 (2004)
Mexico: Internal Regulations of the Health Secretariat of 19 January 2004
11. Efficient and cost-effective spending on essential medicines
Philippines: National Health Insurance Act (2013), Republic Act No. 7581 (1992), Republic Act No. 9502 (2008)
Indonesia: Regulation No. 28/2014 (2014), Law No. 36/2009 (2009)
12. Financial protection of the poor and vulnerable
Chile: Ministerial Decree No. 1 (2006), Law No. 19966 (2004), Law No. 20850 (2015)
Colombia: Law No. 1751 (2015)
Jordan: Civil Health Insurance of 2016, Decision of Council of Ministers No. 5157 on 13/8/2014, Instructions (to include pregnant women in civil
health insurance) No. 9 (2006), Instructions No. 3 (2008)
Health Policy and Planning, 2019, Vol. 34, Suppl. 3 iii53
and Mexico and Rwanda (in relation to pharmacy services and code
of ethics).
A detailed complaints procedure for patients who experience
alleged violations of their health rights is described in legislation
from South Africa, Ghana, and Indonesia. Innovative accountability
mechanisms include a grievance committee at each health institution
to decide on complaints (Philippines), a patient ombudsman to initi-
ate or pursue complaints (South Africa), and patient rights units at
health centres (Turkey). Most remaining countries reference a com-
plaint or dispute settlement mechanism in health law (Nigeria,
Rwanda, Tanzania, Algeria, Uruguay, Chile, Mexico). No account-
ability and redress mechanisms were identified in Tunisian,
Moroccan or Jordanian law.
Selection of essential medicines
In Colombia, Ghana, Indonesia and Nigeria, the concept of essential
medicines informs the pharmaceutical benefits package or the medi-
cines provided in public centres, and their selection criteria, proced-
ure and periodicity. Pharmaceuticals in other UHC packages are
referred to as those on the national drug list (Rwanda), national for-
mulary (Chile and Uruguay), explicit medical benefits (Mexico) and
reimbursed medicines (Algeria). In Mexico, the criteria for prioritiz-
ing essential services are: the financial sustainability of the system,
epidemiological profile and health needs, level of medical attention,
which interventions are already covered and the principles of equity
and distributive justice.
Government financing
Nigeria is the only country to codify the State duty to allocate funds
(specifically 20% of the Basic Health Care Provision Fund) to pro-
vide essential medicines, vaccines and consumables for primary care.
Colombia, Mexico, the Philippines and Turkey have a similar text
but lack an explicit focus on essential medicines. In the Philippines,
the government guarantees the financial viability of the health insur-
ance program, which includes pharmaceuticals.
Pool user contributions
Mandatory pre-payment of UHC contributions is codified in domes-
tic law in Colombia, Chile, Ghana, Indonesia, Jordan, Mexico,
Morocco, the Philippines, Rwanda, Tunisia and Turkey. These laws
require user contribution toward health insurance except for those
unable to pay.
International assistance and technical cooperation
Mexico is the only country to embed technical cooperation with the
international community for health technology assessment in law.
Chilean law permits contributions from the international commu-
nity to the Fund for High-Cost Diagnostics and Treatments.
Colombia and Chile are also part of the Andean Agreement
Decisions (called REMSAA resolutions) for medicines. Other coun-
tries engage in international cooperation and technical assistance for
other health matters (Indonesia, Nigeria, Turkey, South Africa).
Efficient and cost-effective spending
The principle of efficient/cost-effective spending and related policy
measures are codified in legislation from Colombia, Chile, Mexico,
Uruguay, Indonesia, Turkey and the Philippines. Mechanisms for
efficiencies include a positive list for health insurance (Jordan,
Uruguay) that is based on prioritization (Chile, Mexico), exclusion
criteria for medicines reimbursement (Colombia) based on health
technology assessment (Indonesia, the Philippines), reference pricing
(Algeria, Tunisia, Morocco), price ceilings/maximum retail prices
(Rwanda, Philippines), regular pricing review (Ghana), generic pro-
motion and/or substitution (Ghana, Algeria, Morocco, Mexico,
South Africa) and the establishment of a national committee on
medicines pricing (Turkey, Colombia) or a committee to study medi-
cines prices (Algeria). Of notable mention is the Philippine
[Medicines] Price Act that prohibits profiteering and permits medi-
cines price freezes in emergency situations or excessively high prices.
Financial protection of vulnerable groups
The government finances universal access to basic health insurance
for the impoverished in Mexico, the Philippines, Indonesia,
Colombia and Chile. In Jordan, healthcare is provided free of charge
to pregnant women and children, and to the poor who opt-in to in-
surance for a substantially reduced fee. Vulnerable groups and the
impoverished are conditionally exempt from contributions for
health services in Moroccan, Nigerian, Rwandan, Tanzanian,
Ghanaian and Turkish law.
Care is provided free of charge in public centres in Algeria (for
people in difficulty), Tunisia (preventative and general health serv-
ices up to a geographic quota), South Africa (primary care to all and
health services to pregnant women and children under 6 years) and
Rwanda (medicines and reproductive health care).
Trends
We identified trends (described below), but, no significant relation-
ships between specific principles and income economies.
Discussion
Our study presents an assessment tool for access to medicines in na-
tional law and a cross-national snapshot of legal texts from 16 most-
ly LMICs. Legal rights and State obligations toward medicines are
often embedded in national UHC law, while most principles for
good governance are much less common. Some technical principles
to implement medicines affordability and financing are frequently
embedded in national UHC law (i.e. pooled user contributions and
financial coverage for the vulnerable), while other principles are in-
frequent (i.e. sufficient government financing) to almost absent (i.e.
seeking international cooperation). We also identified several trends
in the legal text of countries from different levels of development
(see below). To our knowledge, this is the first study to provide an
in-depth qualitative analysis of legal text for access to medicines by
systematically collecting and assessing domestic legislation against
an assessment tool based on WHO’s policies on essential medicines
and international human rights law. Our assessment tool serves as
both a checklist for assessing national law and policy, and a ‘wish
list’ to guide legal reform.
Trends in legislation
The core purpose of this research was to fill a critical gap in know-
ledge by describing and comparing legal provisions for access to
medicines. In addition to this objective, we identify three legislative
trends more common (albeit not significant) in the upper-middle in-
come countries (and those recently graduated to high income) than
low and lower-middle income countries that we sampled. These
relationships should be interpreted as hypotheses for further explor-
ation in a larger sample of countries and/or more data points, as
follows.
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Trend 1: Explicit individual rights and state obligations
Affluent countries tend to codify universal entitlements and govern-
ment duties. Some even include the right to free care at public health
centres (Algeria, South Africa). This vague entitlement lacks clear
State obligations and lines of accountability. On the other hand, less
affluent countries generally refrain from guaranteeing the right to
basic healthcare for all.
Some countries from all economic classes protect public health
in legislation by prohibiting the denial of emergency medical treat-
ment (Nigeria, Algeria, South Africa). This legal guarantee concerns
only ad-hoc care for the immediate continuation of life; it fails to
take a holistic approach to health that includes disease prevention
and health promotion in the absence of illness and treatment of
chronic diseases.
Trend 2: Clear boundaries to entitlements and obligations
Inevitable boundaries must be established for basic health packages.
No government can provide universal access to all possible health
interventions. Affluent countries tend to limit the scope of medicines
provided by adopting the principle of essential medicines and mech-
anisms for their selection in UHC law. These countries also often
recognize the principle of cost-effectiveness in relation to medicine
selection/reimbursement and use health technology assessment
(HTA) as the mechanism. HTA is an objective, transparent and pre-
dictable method for establishing the boundaries of an essential
health services package. It also shapes the population’s legitimate
expectations about which health interventions they are entitled to
under UHC.
Conversely, less affluent countries define patients’ entitlements
to health interventions based on the principle of available public
resources (Nigeria, Tunisia). Despite being a recognized principle in
the right to health, the concept of ‘available resources’ yields vague
obligations and opaque entitlements when transplanted in national
legislation. State action and rights realization are difficult to assess
against these flexible standards, complicating the redress of
violations.
Trend 3: Mechanisms for accountability and redress
Legislation in affluent countries affirms the right to hold the govern-
ment accountable and outlines procedures to seek redress for rights
violations. The Turkish Patient Rights Regulation entitles patients
with health needs that cannot be met presently to request the object-
ive justification of the State’s priority ranking on the basis of medic-
al evidence. The right to question State decisions to provide some
medicines but not others, and to receive a response, is the essence of
accountability. South Africa has introduced a Patient Ombudsman
who is responsible for investigating cases of rights violations in
healthcare, based on complaints or his/her own initiative.
While less affluent countries do include some mechanisms for ac-
countability and redress in their UHC laws, these are often limited
to the (contributing) members of UHC schemes thereby excluding
the general public who is not eligible for or cannot afford coverage
(Ghana, Tanzania and Rwanda).
Policy implications for WHOMember States
Our findings respond to the legitimate concerns of policy makers
who hesitate to embed human rights principles in domestic law out
of concern that they may trigger (further) rights-based medicines liti-
gation. We provide a menu of principles and legal texts that, when
applied together, may help to prevent such spurious claims. These
texts establish health entitlements with boundaries through objective
criteria (including cost effectiveness), transparent and participatory
decision-making processes, and non-judicial accountability mecha-
nisms to redress violations before having to resort to the courts.
Recognizing the legal boundaries of the right to access to medicines
informs patients’ reasonable expectations of their health system. It
can also protect against excessive or unreasonable claims for imme-
diate access to treatments at any cost. Starting from this basic pack-
age, governments should apply the human rights principle of
progressive realization by continuously and expeditiously expanding
the boundaries of access to medicines for all (Perehudoff et al.,
2016).
National law makers can undertake a ‘check-up’ of access to
medicines using our assessment tool to identify strengths and weak-
nesses in existing domestic law. Our assessment tool and the ex-
ample legal text can also be used as a guide for writing future
legislation (Table 3). Particularly, less affluent countries may seek
inspiration from the language that more affluent nations codify to
develop their UHC schemes and scale-up access to medicines.
Policy implications for WHO
WHO should develop a publicly accessible online repository of na-
tional health legislation, as echoed by other global health researchers
(Attaran et al., 2012). WHO should also publish technical advice
for Member States legislating for access to medicines in UHC
schemes, in line with the goal of WHO’s 2016–30 Medicines &
Health Products Strategic Programme (WHO, 2017). This advice
can use our assessment tool as a starting point and expand on the
examples presented. Our examples translate some recommendations
of the WHO Consultative Group on Equity and UHC for making
fair choices toward UHC into provisions for domestic law (WHO
Consultative Group on Equity and Universal Health Coverage,
2014). WHO’s technical advice could especially catalyse national
governments to embed in their domestic legislation some of the
under-addressed principles we identified (i.e. duty of government to
sufficiently finance essential medicines and to seek international
assistance).
Monitoring bodies (i.e. WHO, Office of the High Commissioner
for Human Rights) can use our results to expand their indicator of
government commitment to health rights, which is currently a right
to health in constitutional or other national law (Office of the High
Commissioner for Human Rights, 2012). Other sub-indicators could
track specific State duties in national health legislation, such as for
(1) the control of medicines prices, and (2) the sufficient financing of
essential medicines for the poor and vulnerable. Embedding these
sub-indicators in national law may have a more direct effect on
patient-level access than governments codifying a constitutional
right to health. Legalizing these State obligations can also support
accountability and redress if rights are violated.
Future research
Our study of 16 mostly LMICs does not investigate other countries
making important strides toward UHC, such as Thailand, Viet
Nam, and Kyrgyzstan, because we lacked the language capacity.
Future research should contribute additional analyses of legislation
from these and other LMICs countries with UHC.
The private sector plays a crucial role in developing, manufactur-
ing and supplying medicines, and is increasingly active in UHC
schemes as a health insurer and provider (Chapman, 2016b). Future
research should continue to examine rights-based legal approaches
to regulating the private sector in the context of UHC (Hallo De
Wolf and Toebes, 2016; Tsevelvaanchig et al., 2018).
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National policies, particularly for pharmaceuticals, health and
intellectual property, can instruct the development of health law or
substitute it entirely by directing State policies and programming.
Future research should investigate the content, implementation and
impact of national policies in relation to access to medicines as part
of the right to health.
The present study of UHC ‘law on the books’ does not examine
the important question of how these laws are implemented in prac-
tice. In a different study, we conducted a follow-up report of eight
right to health indicators of access to medicines in 194 countries
(Perehudoff et al., 2018). We did not find any relationship between
having a constitutional law supporting essential medicines or na-
tional medicines policy and process or outcome indicators relevant
for the right to health (i.e. government spending on medicines, na-
tional availability of essential medicines, childhood immunization
rates). However, our analysis did not include UHC legislation, was
at a high level of abstraction and had data from fewer than half of
the expected data points. Therefore, we recommend that future
studies elucidate how the laws in the present study are imple-
mented through in-depth country case studies with more detailed
and disaggregated sub-indicators, possibly based on the 24 indica-
tors presented by the Lancet Commission on Essential Medicines
Policies (Wirtz et al., 2016). Subsequent research should also study
whether the human rights principles we investigated help improve
governance, implementation and health outcomes for a more
equitable and universal provision of healthcare in practice
(Tremper et al., 2010).
Strengths and limitations
First, although our sample is not representative of all LMICs with
UHC, it includes countries from all world regions with a diversity of
legal traditions and income economies. Most LMICs should be able
to locate a comparable country in our sample and learn from its
examples.
Second, we minimized the risk of reporting bias by working with
multiple, trained research assistants fluent in the national language.
We also verified our collection of legislation and preliminary find-
ings with national experts, except Nigeria and Algeria. Our sources
are more objective than similar studies that rely on interpretations
of law and policy in academic literature and from key informants.
Yet, our conclusions only reflect the retrievable laws and may under-
estimate the observed trends.
Third, to minimize the risk of incorrect translations or inconsist-
ent interpretation, all research assistants were trained in the stand-
ard terminology and definitions of the 12 principles. Translations
from French, Indonesian and Spanish were peer reviewed.
Conclusion
This is the first study to systematically map, collect, and assess na-
tional UHC legislation for attributes related to access to essential
medicines, particularly for vulnerable groups. Our research offers
domestic law makers an assessment tool that is both a checklist and
a wish list for legal reform for access to medicines. We present
examples of legal texts from a range of mostly LMICs providing es-
sential medicines through UHC. These examples may inspire other
WHO Member States to adopt a human rights-based legal frame-
work for universal access to medicines and sustainable development;
they may also support the WHO Medicines & Health Products
Strategic Programme 2016–30 to develop model legislation for med-
icines reimbursement (goal 7).
Supplementary data
Project tools, case studies, and data are available at http://healthandgender.
org/accesstomedicines.html. Supplementary data are available at Health
Policy and Planning online.
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